

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
13 November 2003 (13.11.2003)

PCT

(10) International Publication Number  
WO 03/093308 A1

(51) International Patent Classification<sup>7</sup>: C07K 14/47

(81) Designated States (*national*): JP, US.

(21) International Application Number: PCT/EP03/03663

(84) Designated States (*regional*): European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(22) International Filing Date: 8 April 2003 (08.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02076715.8 29 April 2002 (29.04.2002) EP

(71) Applicant (*for all designated States except US*): SOCI-  
ETE DES PRODUITS NESTLE S.A. [CH/CH]; P.O. Box  
353, CH-1800 Vevey (CH).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): JULLERAT, Mar-  
cel-Alexandre [CH/CH]; Ch. Praz-Dom-Nicod 10, Vers-  
chez-Les-Blancs, CH-1000 Lausanne 26 (CH). ROBERT,  
Marie-Claude [CH/CH]; Rte de Berne 69, CH-1010 Lau-  
sanne (CH).

(74) Agent: WAVRE, Claude-Alain; Avenue Nestlé 55,  
CH-1800 Vevey (CH).

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations JP, European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations JP, European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)*
- *of inventorship (Rule 4.17(iv)) for US only*

**Published:**

- *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METALLO PROTEINASE INHIBITORY AGENT

(57) Abstract: The present invention relates to an active agent, in particular a metalloproteinase inhibitory agent comprising casein-derived peptides obtained by hydrolysis of casein by a food grade bacteria. The invention also relates to the manufacture of a agent, in which a food grade bacteria of the genus *Lactobacillus helveticus* is contacted with casein in order to perform an hydrolysis and obtain casein-derived peptides exhibiting metalloproteinases inhibitory property. The present invention also concern the isolated and purified inhibitory peptides obtained by hydrolysis of casein by the said bacteria.

WO 03/093308 A1

**METALLO PROTEINASE INHIBITORY AGENT**

5 The present invention relates to an active agent, in particular a proteinase inhibitory agent. More specifically, this invention relates to metalloproteinase inhibitory agent comprising casein-derived peptides.

10 The degradation of extracellular matrix (ECM) is a very complex process and is part of many pathological and physiological processes. The proteolytic degradation of the extracellular matrix therefore plays a crucial role in cancer invasion as also in non-neoplastic tissue

15 remodelling processes. The role of the matrix-metalloproteinases (MMPs) enzymes in the tumor cell-mediated extracellular matrix proteolysis is well established. Thus, by regulating composition and integrity of ECM, MMPs play an important role in the control of

20 signals elicited by matrix molecules and regulate cell proliferation, differentiation and cell death. MMPs are ubiquitous enzymes and prostate, breast, bone as well as colon tumor cell lines have been shown to secrete MMPs in vitro. The MMP family has over 20 members that cleave

25 various components as various as fibronectin, gelatin and collagen for example. Among the MMPs family, MMP-2 and MMP-9 have been identified in cancer cells and the active forms were detected more frequently in malignant than in benign breast carcinoma. MMP-2 may thus be considered as a

30 key enzyme in ECM remodeling involved in tumor invasion and metastasis.

Beyond cancer and tumor invasion MMPs are also associated with a wide variety of normal and pathological conditions involving matrix degradation and remodeling. MMPs are thus involved in some physiological processes like foetal  
5 development, angiogenesis, bone formation and resorption. Indeed, bone resorption models showed that MMP-9 is specifically required for the invasion of osteoclasts and endothelial cells into the discontinuously mineralized hypertrophic cartilage that fills the core of the  
10 diaphysis. MMPs have also been reported to be involved in pathological processes like arteriosclerosis, arthritis, autoimmune diseases, periodontitis, tissue ulceration and of course cancer invasion and metastasis.

15 It is also known that the proteolytic activity of the MMPs involved in ECM degradation may be regulated by their endogenous inhibitors, the tissue inhibitors of metalloproteases (TIMPs). These inhibitors influence the activation of the metalloproteases and act to modulate  
20 proteolysis of ECM, notably during tissue remodelling and inflammatory processes. There are also synthetic inhibitors like marimastat for example, a butanediamide derivative with a IC50 in the micromolar range. Inhibitors of MMPs generally fall into three pharmacological categories :  
25 collagen peptidomimetics and non-peptidomimetics, tetracyclin derivatives and bisphosphonates.

MMPs inhibitors would therefore have the potential to inhibit tumor growth by preventing local invasion and by  
30 inhibiting tumor angiogenesis. The current existing non-endogenous inhibitors present the drawback of a poor oral bioavailability as well as high cost. Moreover since these

are synthetic molecules, the synthesis route is generally cumbersome and necessitates purification step in order to recover functional mixtures.

5 Therefore it remains a need for a simple procedure for obtaining a metallo-proteinase inhibitory agent that would be cheap and easy to prepare and that could also be used in a food product or as nutraceutical food product.

10 It is also an object of the invention to provide a method for inhibiting metalloproteinases, preferably matrix-metalloproteinases.

It is another object of the invention to provide an agent effective for inhibiting metalloproteinases,  
15 preferably matrix-metalloproteinases.

It is yet another objective of the present invention to provide a method for preparing an agent effective for inhibiting metalloproteinases, preferably matrix-metalloproteinases.

20 Accordingly, the present invention relates to a metallo-proteinases inhibitory agent, in particular a matrix-metalloproteinase' inhibitory agent, comprising casein-derived peptides obtained by hydrolysis of casein by a food grade bacteria.

25 The present invention also concerns the use of the inhibitory agent according to the present invention, systematically, locally or topically for inhibition of metalloproteinases, in particular matrix-metalloproteinases.

30 One other aspect of the present invention enable the manufacture of a metalloproteinases inhibitory agent, in

particular a matrix-metalloproteinases inhibitory agent, comprising the steps of :

- preparing a solution of casein and food grade bacteria,
- 5       - holding said solution under conditions effective to partially hydrolyse the casein to provide a metalloproteinases inhibitory agent, in particular a matrix-metalloproteinases inhibitory agent, containing casein-derived peptides,
- 10       - stopping the hydrolysis and
- optionnaly recovering the inhibitory agent from the solution.

The expression "food grade bacteria" refers to any bacteria that has not any harmful effect on human health or  
15 that has the GRAS (generally recognized as safe) status. Such bacteria maybe selected from the group consisting of Lactobacilli and Bacilli. The preferred bacteria particularly suitable for the purpose of the process according to the present invention may be *Lactobacillus*  
20 *helveticus* ssp, more particularly *Lactobacillus helveticus* deposited under the N°I-2864 at CNCM, Institut Pasteur, Rue du Dr Roux, Paris, on April 29, 2002.

An other aspect of the present invention relates to the manufacture of a metalloproteinases inhibitory agent,  
25 in which isolated proteolytic enzymes of the preferred food grade bacteria are used instead or in combination with the bacteria.

A further aspect of the present invention relates to the manufacture of a fermented dairy product containing a  
30 metalloproteinases inhibitory agent, preferably matrix-metalloproteinases inhibitory agent, comprising the steps of :

- contacting lactic acid bacteria with milk,
- fermenting the obtained mixture to obtain a fermented dairy product, under conditions to partially hydrolyse the casein of the milk into casein-derived peptides to provide a fermented dairy product containing a metalloproteinases inhibitory agent, in particular a matrix-metalloproteinases inhibitory agent.

It is also a further object of the present invention to provide inhibitors of metalloproteinases, in particular matrix-metalloproteinases, in the form of single-polypeptide-chain peptides. Thus, particularly preferred inhibitors according to the present invention are selected from the group consisting of the single-polypeptide-chain peptides set forth in SEQ ID N° 1 to 8, having the amino acid sequence:

E-N-L-L-R-F-F-V-A-P-F-P-E-V-F,  
 E-N-L-L-R-F-F-V-A-P-F-P-E-V-F-G-K-E-K-V,  
 N-E-N-L-L-R-F-F-V-A-P-F-P-E-V-F,  
 L-N-E-N-L-L-R-F-F-V-A-P-F-P-E-V,  
 E-N-L-L-R-F-F-V-A-P-F-P-E,  
 N-E-N-L-L-R-F-F-V-A-P-F-P-E,  
 G-L-P-Q-E-V-L-N-E-N-L-L-R-F-F and  
 F-V-A-P-F-P-E-V-F-G-K-E-K-V-N-E-L-S-K-D-I-G-S

or substantially homologous ones.

Other particularly preferred inhibitors according to the present invention are selected from the group consisting of the single-polypeptide-chain peptides set forth in SEQ ID N° 9 to 16, having the amino acid sequence:

L-H-L-P-L-P-L-L  
 L-H-L-P-L-P-L-L-Q

- 6 -

N-L-H-L-P-L-P-L-L-Q

N-L-H-L-P-L-P-L-L

N-L-H-L-P-L-P-L-L-Q-S-W

D-V-E-N-L-H-L-P-L-P-L-L-Q-S-W

5 V-E-N-L-H-L-P-L-P-L

V-E-N-L-H-L-P-L-P and

L-P-L-L-Q-S-W-M-H-Q-P-H-Q-P-L-P-P-T-V-M-F-P-P-Q-S

or substantially homologous ones.

- 10 The expression "substantially homologous" as used here means a degree of homology in excess of 70%, preferably in excess of 80%.

The amino acids represented by the foregoing abbreviation  
15 are set forth in the description of the preferred embodiment.

The present invention also concerns the use of the inhibitors according to the present invention, systematically, locally or topically for inhibition of  
20 metalloproteinases, in particular matrix-metalloproteinases.

It is yet an other aspect of the present invention to provide pharmaceutical composition comprising an amount of inhibitors of metalloproteinases, in particular matrix-  
25 metalloproteinases, effective to reduce activities and/or functions of such metalloproteinases, in particular matrix-metalloproteinases.

30 Furthermore, other biologically active, improved analogs of the metalloproteinases inhibitors of the present invention

may be obtained by replacing various other amino acids in the inhibitor amino acid sequence.

In the present context, the term "metalloproteinase" 5  
embrass any kind of metal dependant proteolytic enzymes.  
Therefore, this term encompasses the matrix-  
metalloproteinases as described in the introduction of the  
present application such as MMP-1, MMP-2, MMP-3, MMP-4,  
MMP-5, MMP-6, MMP-7, MMP-8, MMP-9, MMP-10, MMP-11, MMP-13,  
10 MMP-14, MMP-15, MMP-16, MMP-17, MMP-18, MMP-19, MMP-20,  
MMP-21, MMP-22, MMP-23, MMP-24, MMP-25, MMP-26, MMP-27, and  
MMP-28. However, it also concerns other metal dependant  
proteinases like angiotensine converting enzyme (ACE),  
endothelium converting enzyme (ECE) and neutral  
15 endopeptidase since all these enzymes work according a  
similar chemical mechanism.

It has thus been surprisingly found that such agent  
shows a noticable proteolytic inhibitory effect regarding  
metallo-proteinases activity, and particularly regarding  
20 matrix metallo-proteinases activity. The present invention  
encompasses also the use of the inhibitors according to the  
present invention or composition comprising casein-derived  
peptides obtained by hydrolysis of casein by a lactic acid  
bacteria for the inhibition of metallo-proteinases,  
25 particularly matrix metallo-proteinases.

The inhibitors and inhibitory agent according to the  
present invention may be used for inhibition of  
metalloproteinases, particularly matrix-metalloproteinases,  
and therefore applied for inhibition of cancer invasion and  
30 metastasis, tissue ulceration, arthritis and periodontitis  
as well as inhibition of osteoclasts.



Such an agent is particularly suitable for use in food products, such as fermented and non fermented dairy products like yoghourts or fermented dairy beverages, for example.

5        Such agent may also be used in chewing-gum, candies or oral supplements, for example, for the local inhibition of metalloproteinases, in particular matrix-metalloproteinases, involved in periodontitis. In a similar way of use, the agent according to the invention may also be  
10        used in toothpaste or mouth-bath, for example, for the same purpose. The present agent may also be advantageously used in petfoods or treats for pets, for example. Indeed, a particular pet disease called Feline Osteoclastic Resorptive Lesion is suspected to be induced by local over-  
15        activity or activation of matrix-metalloprotease on the jaws of cats. The proteases thus activated induce the resorption of jaw-bone that will finally lead to loss of teeth and dental-incapacity of the pets, particularly cats. Therefore the local use of the inhibitors or inhibitory  
20        agent according to the present invention for reducing feline osteoclastic resorptive lesions presents a preferred aspect of the present invention.

Figure 1 describes peptide sequences from RP-HPLC  
25        subfractions 24-27 of fraction 6 from GPC showing a common amino acid sequence. Peptides from the candidate region retrieved in inactive fraction are shown in black whereas peptides characterised in subfractions twenty-four to twenty-seven and showing activity are shown in grey. A  
30        refers to Alpha-casein and B refers to Beta-casein.

## Material and methods

### HPLC/ Mass spectrometer

5

- Finnigan Mat ion-trap LCQ mass spectrometer (Thermo Finnigan, San Jose, CA, USA)
- Finnigan Mat Spectra System P4000 (Thermo Finnigan, San Jose, CA, USA)
- 10 - Finnigan Mat Spectra System AS3000 (Thermo Finnigan, San Jose, CA, USA)
- SEQUEST developed by John Yates and Jimmy Eng at the University of Washington and is protected by U.S. Patent 5,538,897
- 15 - Agilent 1050 Series Modules and Systems for HPLC (Agilent Technologies, Palo Alto, CA, USA)

### Columns for HPLC/MS

- 20 - Superdex 75 HR 10/30 (Amersham Pharmacia Biotech, Duebendorf, Switzerland)
- Column C8, 208TP54, pore size: 300 Å, particule size: 5µm, inner diameter: 4.6 mm, length: 250 mm (Vydac, Hesperia, California, USA)
- 25 - Nucleosil C18, pore size: 100 Å, particule size: 5µm, inner diameter: 1mm, length: 250mm (Macherey-Nagel AG, Oensingen, Switzerland)
- Preparative C18, 218 TP152050, pore size: 300 Å, particule size: 10-20 µm, inner diameter: 50mm, length: 250 mm (Vydac, Hesperia, California, USA).
- 30

Peptide synthesis

- 5           - ACT 348 Omega Multiple Peptide Synthesizer  
(Advanced ChemTech Inc, Louisville KY, USA)

Culture of lactic acid bacteria

- 10           Bacteria were grown without shaking, overnight in  
sterile MRS broth at 40°C in a water bath. UHT-skim  
milk was inoculated at 2% from the overnight MRS  
culture and fermentation occurred at 37°C. Bacteria  
were finally harvested as the pH of the fermented milk  
15           lied below 4.5. The pH of the fermented milk was  
readjusted to 5.2 with NaOH and 2% of tri-sodium  
citrate were added to solubilize the caseins. The  
fermentation solution was allowed to rest for 10 min  
at RT.  
20           Subsequently, bacteria were centrifuged at 3'700g, 4°C  
during 10 min, washed 3 times and resuspended in tris-  
maleate buffer.

- 25           The optical density of the suspension was measured,  
assuming that the increase in cell suspension  
turbidity of 1.0 unit of absorbance at 600 nm  
corresponds to 10<sup>8</sup> cells/ml.

- 30           - Buffer: Tris-maleate (30 mM): 3.63 g  
tris(hydroxymethyl)-aminomethane, 3.48 maleic acid

and 2.94 calcium chloride were added to 1 liter H<sub>2</sub>O and the pH was adjusted to 7.5 with NaOH.

5

#### Casein hydrolysis with lactic acid bacteria

The equivalent of OD=80 or  $8 \times 10^9$  cells per ml (final conc.) bacteria were incubated at 37°C in a water bath with sodium caseinate (4mg/ml) in 30 mM tris-maleate buffer. Samples were taken as a function of time (maximum: 5 hours). The proteolysis was stopped by centrifugation at 14'000g and the supernatant was recovered. The samples were conserved frozen at -20°C for subsequent analyses.

- Buffer: Tris-maleate (30 mM): 3.63 g  
tris(hydroxymethyl)-aminomethane, 3.48 maleic acid,  
2.94 calcium chloride were mixed, the pH adjusted with NaOH to 7.5 and the solution completed to 1 liter with H<sub>2</sub>O.

#### Casein antigenicity ELISA test

Microtitration plates were coated with caseinate in coating buffer at a concentration of 50 µg/ml and incubated overnight at 4°C.  
Four washing steps with phosphate buffered saline-Tween-20 solution were performed before each successive reagent addition. The unoccupied sites were

blocked with fish gelatine buffer during 30 min. Test samples dilutions and a standard solution were mixed with rabbit anti-casein IgG-polyclonal antibodies (dilution 1 : 10'000) and incubated for 1 hour at RT. A peroxidase labelled second antibody (dilution 1 : 2'000) was then added and incubated for 30 min. Subsequently, the reaction substrate (o-phenylene-diamine, OPD) was added for 5-10 min and the reaction stopped with 5% H<sub>2</sub>SO<sub>4</sub> (final conc.). The plate was read at 490 nm.

- *Coating buffer*: 795 mg Na<sub>2</sub>CO<sub>3</sub> and 1.465 g NaHCO<sub>3</sub> were added to 500 ml H<sub>2</sub>O (pH 9.6).
- *PBS buffer*: 8 g NaCl, 200 mg KH<sub>2</sub>PO<sub>4</sub>, 200 mg KCl and 2.9 Na<sub>2</sub>HPO<sub>4</sub> dodecahydrate were added to 1 liter H<sub>2</sub>O.
- *PBS-Tween 20*: 0.25 g Tween-20 were added to 1 liter PBS.
- *Fish gelatine buffer*: 0.5% fish gelatine in PBS buffer.
- *Substrate buffer*: 0.51 g citric acid, monohydrate and 1.84 g Na<sub>2</sub>HPO<sub>4</sub> were added to 100 ml H<sub>2</sub>O. 15 minutes before use 40 mg OPD, and finally 40 µl Perhydrol® were added.

#### 25 Leucine aminopeptidase activity test

The leucine aminopeptidase activity was measured according to the procedure described by Sarath et al (Sarath, G., R. De La Motte, and F.W. Wagner. 1989. Protease assay methods. In Proteolytic enzymes: A practical approach. R.J. Beynon and J.S. Bond, editors.

IRL Press, Oxford. 25-56.) with some modifications. The assay was performed in a microtiter plate. In each well, 180µl of 100mM phosphate buffer, pH 6.5, 10µl enzyme solution and 10 µl H-Leu-pNA (10 mM in DMSO) were mixed and incubated at 37°C for 1 hour. The absorbance at 405 nm was measured as a function of time (molar absorption coefficient,  $\epsilon=10^5 500 \text{ M}^{-1}\text{cm}^{-1}$ ).

Initial velocities are proportional to the enzyme concentration. The difference in absorbance  $\Delta A_{400}$  is equivalent to the absorbance read during the enzymatic reaction minus the absorbance from the blank reaction (negative control).

The result is expressed in µmol p-nitroaniline formed per ml enzyme solution per minute [U/ml]

One leucine aminopeptidase unit (LAPU) is defined as the amount of enzyme required to liberate one micromole of p-nitroaniline per minute at 37°C.

#### Enzymatic hydrolysis of an active fraction from sodium caseinate hydrolysate

Fractions showing antiproliferative character were hydrolysed in a first step with 1% alcalase for 1 hour at 55°C in a thermomixer at 600 rpm. In a second step, the hydrolysate was incubated with 1% acid proteinase A for 1 hour at 50°C in a thermomixer at 600 rpm. The enzymatic reaction was stopped heating the sample 5 minutes at 95°C. Enzymes were finally removed from the

hydrolysate using Ultrafree®-0.5 centrifugal filter units having a nominal molecular weight limit of 10'000 Da.

- 5 Percentages of enzyme given here represent the enzyme proteinic content vs. the hydrolysate proteinic content.

10 Culture of human intestinal epithelial cells (IECs) and proliferation assay

- Human colonic adenocarcinoma cell line HT29 (ATCC: HTB-38) from the American Type Culture Collection (ATCC, Manassas, VA).
- 15 - DMEM, high glucose (4.5 g/l), with stable glutamine (BioConcept, AMIMED, Allschwil, Switzerland)

Undifferentiated cells (passages 45-78) were maintained in glucose-containing DMEM supplemented with 10% FCS at 37°C in a 5% CO<sub>2</sub>/air incubator. Culture medium was changed every two days until the cell monolayers reached 50% confluence. For stimulation assays, HT-29 cells were plated at  $1.2 \times 10^4$  cells/well in 96-well flat-bottom plates. After incubation for 4 days, the amount of cells present in the wells before incubation with the samples was assessed adding neutral red solution in 4 wells and incubating the plate for 45 min. The HT-29 cells were then washed twice with serum-free media (inclusive the wells with neutral red solution). The wells coloured with neutral red remained from now on free of any media.

HT-29 cells were then incubated 24 hours respectively in the presence of 80 µg (hydrolysed) sodium caseinate samples in 200 µl DMEM, in 200 µl serum-free medium (blank), in 200 µl medium with serum (positive control) or in 0.9% saline solution (negative control). After incubation, the cells were washed twice with serum-free media, neutral red solution was then added and the cells incubated for 45 min. All wells were washed three times with saline water and residual solution was removed hitting the plate gently on a tissue. The dye was finally extracted with 100 µl of a extraction solution and the optical density measured at 540 nm. The optical density measured correlates with the number of cells present in the wells.

The proliferation was calculated by the difference in absorbance between the cells having been incubated 24 hours with sodium caseinate samples, with serum-free medium, with medium containing serum or with 0.9% saline solution and the cells before incubation.

The difference in absorbance  $\Delta A_{540}$  from the blank (cells incubated with serum-free medium) was normalized. The results were then expressed as percentage with respect to the blank.

- Culture medium with serum: DMEM was supplemented with 10% decompemented FCS and 1% Penicillin-Streptomycin. The solution was sterile filtered Ø 22 µm.



- Culture medium, serum-free: DMEM was supplemented with 1% Penicillin-Streptomycin. The solution was sterile filtered 22 µm.
- Extraction solution: 1% acetic acid, 50% EtOH in water.
- Neutral red stock solution: 617 mg of Neutral Red were dissolved 100 ml in 0.9% NaCl solution. The solution was autoclaved at 120°C for 15 min and stored at 4°C in light -shielded bottles.
- Neutral red solution: Dilute 3:10 Neutral Red stock solution in DMEM, serum-free. Use this solution for the assay.

Foetal calf serum (FCS) was decomplexed during 30 min at 56°C.

#### Lactate dehydrogenase cytotoxicity test

Cell viability was rigorously measured according to the manufacturer's recommendations (Roche Diagnostics). The test is based on the measurement of lactate dehydrogenase (LDH) activity released from the cytosol of damaged cells in the supernatant.

#### Hydrolysate fractionation by gel permeation

Samples were analysed using a Superdex 75 column with an isocratic elution using 50 mM ammonium acetate, pH 7, as solvent for 65 min. The flow rate was 0.5 ml/min, at pressure of 17-19 bar. Detection was accomplished at 280 and 215 nm.

Prior separation, the samples were heated for 5 min at 90°C and centrifuged at 14'000g in a bench centrifuge. 100 µl supernatant were then injected for analysis and separation. Fractions were collected as a function of their molecular weight.

Finally, the collected fractions were lyophilised and resuspended in H<sub>2</sub>O twice before final lyophilisation. This procedure should ensure the disappearance of any traces of ammonium acetate.

HPLC-solvents were sterile-filtered (Ø 22µm) and sonicated at least 5 minutes to remove any air bubbles.

Hydrolysate fractionation by reverse-phase chromatography, using a C8 column

Since 100 µl caseinate hydrolysate had been fractionated on the Superdex75 column, the resulting lyophilised gel permeation fractions were resuspended in 100 µl H<sub>2</sub>O for testing the inhibition of cell proliferation. The concentration of each peptide in a fraction was thus comparable to the concentration of the peptide in the initial hydrolysate sample.

Samples (100 µl) with a molecular weight between 5'000 and 1'000 Da were analysed using a C8-column with a linear gradient increase of solvent B in solvent A as follows: 5 minutes isocratic elution at 0%B, 0-50% B in 60 minutes, 50-100% B in 1 minute, 4

minutes at 100% B, change to 100%A in one minute and finally re-equilibration at 100%A during 9 minutes.

5        Samples (100 µl) with a molecular weight lower than  
1'000 Da were analysed using a C8-column with a linear  
gradient increase of solvent B in solvent A as  
follows: 5 minutes isocratic elution at 0%B, 0-35% B  
in 60 minutes, 35-100% B in 1 minute, 4 minutes at  
100% B, change to 100%A in one minute and finally re-  
10        equilibration at 100%A during 9 minutes.

Total time run for both analyses was 80 min and the  
flow rate amount to 0.8 ml/min with a pressure of 105-  
120 bar. The injection volume was 100 µl. Following  
15        chromatographic separation, fractions were collected  
every 2.5 min (2 ml volume). The collected fractions  
were lyophilised and resuspended in H<sub>2</sub>O twice before  
final lyophilisation. This procedure should ensure the  
disappearance of any traces of trifluoroacetic acid.  
20        Finally, the lyophilised fractions were resuspended in  
100 µl H<sub>2</sub>O to ensure that the concentration of each  
peptide before fractionation is the same after  
fractionation.

25        HPLC-solvents were sterile-filtered (Ø 22µm) and  
sonicated at least 5 minutes to remove any air  
bubbles.

- Solvent A: 0.05% TFA in water
- Solvent B: 0.045% TFA, 80% acetonitrile in water

30

ESI-MS/MS

5           Peptides separated by GPC methods were  
characterised using a SpectraSystem HPLC with a C8 or  
a C18 column coupled to the Finnigan LCQ ion trap mass  
spectrometer equipped with an ESI source. The HPLC  
system consisted of a quaternary pump (TSP P4000), an  
10       autosampler (TSP AS3000) and a UV/VIS detector (UV/VIS  
205 from Linear Instruments) equipped with a high  
pressure flow-cell (1.6 µl volume, 2 mm pathlength).  
HPLC flow was directed via 0.005'' ID PEEK tubing to a  
micro flow-splitter with 10% going to the MS and 90%  
15       being collected in a fraction collector. The MS  
instrument was tuned and calibrated using the  
manufacturer's protocols (ThermoFinnigan). The ESI  
source was operated at 4.5 kV and the interface  
capillary heater was set to 200°C. Sheath gas flow was  
20       maintained at flow rates of 50 ml/min.

          All spectra were obtained in positive mode and  
recorded at unit-mass resolution. Automated MS/MS  
spectra were acquired with relative collision energy  
for CID preset at 35% and an isolation width of 1 m/z  
25       units. During an automated run, if an ion was present  
in a scan above a specified threshold, a product ion  
spectrum was acquired. After two product ion spectrum  
scans of the most abundant ion, it was excluded to  
trigger further MS/MS scans ("dynamic exclusion"  
30       option in Xcalibur software package). The second most  
abundant ion, if still above specified threshold,  
could trigger again product ion spectrum acquisition.

Dynamic exclusion allowed the generation of MS/MS spectra of peptide mixtures in peaks not fully resolved by chromatography. The mass spectrometer continued to alternate between MS and MS/MS mode until  
5 the ion intensity dropped below the threshold. The scan range was set at  $m/z$  150.0-2000.0 .

#### *Data analysis*

Full scan MS and MS/MS data acquisition and  
10 analysis was performed with Xcalibur software V1.0 SR1 (Finnigan), including Bioworks V1.0 software package for SEQUEST™ database searches.

Experimentally obtained peptide masses were compared to SwissProt protein database using *PeptIdent* (Peptide  
15 Mass Fingerprinting) and *PeptideMass* programs accessible from the ExPASy Molecular Biology Server of the Swiss Institute of Bioinformatics at the Internet site <http://www.expasy.ch>.

MSMS spectra analysis was performed using the SEQUEST™  
20 program. It correlates uninterpreted MSMS spectra of peptides with amino acid sequences from protein and nucleotide databases. Based on this correlation it determines the amino acid sequence and thus the protein(s) that correspond to the mass spectrum being  
25 analysed. More information can be obtained at the SEQUEST™ Internet site <http://thompson.mbt.washington.edu/sequest>.

#### Peptide synthesis procedure

30

All peptides (400-500 mg) were synthesised on an Advanced Chemtech peptide synthesiser ACE 348 omega.

The  $\alpha$ -amino function of the amino acids was protected with the base labile fluorenyl methoxy carbonyl (Fmoc) and side chains of tri-functional amino acids with acid labile protecting groups, i.e. Arg(Boc)<sub>2</sub>,  
5 Glu(OtBu), His(Trt) and Asn (Mtt).

In general, prior to peptide synthesis, the resin was swollen in dichloromethane (DCM) during 30 min. Peptides were assembled by sequential amino acid coupling on Sasrin resin applying the Fmoc-strategy  
10 <sup>180</sup>. According to the published procedures of automated peptide synthesis, a deprotection /coupling cycle comprises I) a 10 min deprotection of Fmoc amino acid derivative (2 eq) in DMF with Benzotriazol-1-yl-oxy-tris(pyrrolidino)phosphonium hexafluorophosphate  
15 (PyBOP, 2.5 eq) as coupling reagent and N,N-diisopropyl ethylamine (DIEA, 5 eq) as base.

Cleavage of the peptide from the resin was performed with 2% trifluoroacetic acid (TFA) in DCM during 20 min. After treatment, the resin was  
20 separated by filtration and the filtrate concentrated in vacuo. For complete removal of the side chain protection, the peptide was treated with a cocktail of TFA/Triisopropylsilan (TIS)/water (90:5:5, v/v). After 1hour, cold diethyl ether was added to precipitate the  
25 product. The precipitate was collected by centrifugation and lyophilised from a water/acetonitrile (1:1, v/v) solution to afford a colourless solid.

After lyophilisation, the crude product was  
30 purified by preparative RP-HPLC on a C18-column applying a linear gradient from 20%A to 60%A (A: 0.9% TFA in acetonitrile, B: 10% A in H<sub>2</sub>O) over 30 min at

flow rate of 80 ml/min. The eluate was monitored by UV absorption at 214 nm wavelength, appropriate fractions were collected and lyophilised. The peptide was characterised by electrospray ionisation mass spectrometry (ESI-MS) and analytical RP-HPLC.

#### Angiotensin-converting-enzyme inhibitory test

This procedure is a rapid spectrophotometric method utilising the synthetic tripeptide substrate N-[3-(2-furyl)acryloyl]-L-phenylalanylglycylglycine (FAPGG).  $K_m$ -value: 0.3 mM.

FAPGG was hydrolysed to furylacryloylphenylalanine (FAP) and glycylglycine. Hydrolysis of FAPGG resulted in a decrease in absorbance at 340 nm.

The ACE reagent and the ACE Calibrator were reconstituted according to the manufacturer's recommendations.

The assay was performed in quartz cuvetts. 0.05 ml ACE Reagent Solution, 0.05 ml casein hydrolysate and 0.05 ml ACE calibrator were mixed and incubated at 37°C for 10 minutes.

The absorbance at 340 nm was measured as a function of time.

The ACE activity in the sample was determined by comparing the sample reaction rate to that obtained with the ACE calibrator. The results are expressed as percentage with respect to the control.

Matrix metalloproteinase inhibitory test

The assay was performed in microtiter plates. In each single well 1  $\mu$ l enzyme, the inhibitor at the  
5 desired concentration and finally 5  $\mu$ l substrate were added to PBS buffer (pH 7.0-7.5), final volume: 200  $\mu$ l. The reaction mixture was incubated at 37°C for 2 hours. The increase in fluorescence was continuously recorded, exciting at 485 nm and reading the emission  
10 at 530 nm, with a gain of 40.

- *Inhibitors:* - o-phenantroline: 9.9 mg in 25  $\mu$ l DMF (dimethylformamide)  $\rightarrow$  add 1  $\mu$ l (final concentration: 10 mM)  
15 - synthetic inhibitors at different concentrations

- *Substrate:* DQ-gelatine: 1 mg/ml in PBS  $\rightarrow$  add 5  $\mu$ l to the reaction (reaction volume: 200  $\mu$ l) (final concentration: 25 mM)  
20

- *Enzymes:* - MMP-7: stock solution: 1 U/ $\mu$ l  
- MMP-2: stock solution : 0.05  $\mu$ g/ $\mu$ l  
- MMP-9: stock solution: 0.05  $\mu$ g/ $\mu$ l  
25



## Results & Discussion

### Generation of the peptide library with *Lb. helveticus* CNCM I-2864 .....

Following preliminary trials with several LAB  
5 representing the variety of LAB used in dairy products,  
the *Lb. helveticus* NCC 619 strain was selected to  
hydrolyse sodium caseinate in a buffered system.  
Caseinate hydrolysis occurred at 37°C for 5 hours.  
Samples were taken as a function of the time and  
10 proteolysis was stopped by centrifugation of the bacteria  
and recovery of the supernatant. The caseinate  
hydrolysates taken at different times constituted the  
peptide libraries studied below.

### 15 Leucine aminopeptidase test

This test was performed to check that caseinate  
hydrolysis was the action of the extracellular LAB  
proteinase and not the consequence of peptidases'  
20 activities. LAB display a unique cell wall associated  
proteinase which is performing the first step in the  
degradation of proteins. However, many peptidases are  
located in the cytosol of the bacteria and membrane  
leakage could be responsible for their release in the  
25 fermentation medium.

The conversion of leucine p-nitroaniline to p-  
nitroaniline catalysed by leucine aminopeptidase was  
measured in the samples that were previously analysed  
30 by SDS-PAGE and ELISA.

This analysis demonstrated that little aminopeptidases were released from the cytosol of the bacteria into the medium during caseinate hydrolysis.

5           The overall hydrolysis of caseins by aminopeptidases was relatively low, reaching approximately 1% after 5 hours fermentation. Hydrolysis of caseins was thus resulting quasi exclusively from the serine-type extracellular  
10           bacterial proteinase.

#### Characterisation of the peptide library

15           The casein-derived peptide library generated by *Lb. helveticus* CNCM I-2864 ... was characterised using liquid chromatography in combination with mass spectrometry.

#### Fractionation by HPLC

20           The strategy chosen for the fractionation of caseinate hydrolysates was set up in two steps. A first fractionation occurred on a molecular weight basis by gel permeation chromatography. The second fractionation was based on the hydrophobic  
25           interactions of the casein-derived peptides with a C<sub>8</sub>-reverse phase chromatography column.

#### ♦ Superdex 75 gel permeation chromatography (GPC)

30           With a molecular weight standard, retention times were experimented on the Superdex 75 .

Finally, seven fractions were collected after separation of the caseinate hydrolysate using size exclusion chromatography.

5

Fraction's name	F <sub>ion</sub> 1	F <sub>ion</sub> 2	F <sub>ion</sub> 3	F <sub>ion</sub> 4	F <sub>ion</sub> 5	F <sub>ion</sub> 6	F <sub>ion</sub> 7
Retention time [min]	13.8	15.2	16.7	20.5	26.4	32.2	39.0
	-	-	-	-	-	-	-
Molecular weight range [Da]	15.2	16.7	20.5	26.4	32.2	39.0	65.0
	45'000	40'000	35'000	25'000	15'000	5'000	
	-	-	-	-	-	-	<1'000
	40'000	35'000	25'000	15'000	5'000	1'000	

Table 1 : Result of the first fractionation step achieved with Superdex 75 gel permeation chromatography (GPC)

10

#### ♦ C8-reverse phase chromatography

15

Fractions 6 (5'-1'000 Da) and 7 (<1'000 Da) from GPC were further fractionated using reverse-phase chromatography.

20

Reverse-phase chromatography was used in combination with mass spectrometry for the characterisation of the sample. The HPLC flow was directed to a micro flow-splitter with 10% going to the MS and 90% being collected in a fraction collector. Mass spectrometric analysis and collection of fractions were thus performed in the same run, allowing the determination of the exact qualitative peptidic composition of each collected fraction.

25

Thirty-two fractions were collected as a function of the time, every 2.5 min.

Reverse-phase separation led to the identification of around five hundred peptides. All peptides were analysed and characterised using mass spectrometric analysis and in particular MS/MS data.

Mass-spectrometric characterisation of the low molecular weight peptide fractions of the hydrolysates

Reverse-phase HPLC in conjunction with ESI-MS detection of casein-derived peptides in fractions 6 and 7 from GPC resulted in the identification of more than five hundred peptides.

Fragmentation patterns of peptides were obtained by MS/MS analysis of the most intense ions. To perform protein identification, mass spectrometry fragmentation patterns were used to search protein database. This work was done using the SEQUEST browser<sup>®</sup> software. This tool was able to convert the character-based representation of amino acid sequences in a protein database to fragmentation patterns that were compared against the MS/MS spectrum generated on the target peptide.

The algorithm initially identified amino acid sequences in the database that matched the measured mass of the peptide, compared fragment ions against the MS/MS spectrum, and generated a preliminary score for each amino acid sequence. A cross correlation analysis was then performed on the top 500 preliminary scoring peptides by correlating theoretical,

reconstructed spectra against the experimental spectrum. Best scores and the corresponding peptides were then proposed.

5            Fragmentation pattern showed predominance of the products ions at  $m/z$  1053.3 and at  $m/z$  730.8. These two intense signals correspond to fragments issued from internal cleavage near the proline; the strongest signal corresponding to the extension from the proline  
10           in the direction of the C-terminus. Moreover, we saw generation of both the b-type ( $b_2$ ;  $m/z$  292.2,  $b_3$ ;  $m/z$  421.4,  $b_5$ - $b_7$ ;  $m/z$  617.7, 730.8, 787.9,  $b_9$ - $b_{11}$ ;  $m/z$  984., 1140.3, 1197.4 and  $b_{13}$ ;  $m/z$  1441.7) and y-type ( $y_3$ - $y_{14}$ ;  $m/z$  342.5, 489.6, 586.8, 643.8, 800.0, 899.1,  
15           996.2, 1053.3, 1166.5, 1256.6, 1362.7, 1491.8) ions. These types of ions are predominantly generated in low energy collision induced dissociation.

          All these informations demonstrate the validity of the proposed peptide sequence. It was processed in a  
20           similar way for all characterised peptides. Fragmentation patterns with no clear assignable b- or y-type ions were rejected.

          The characterization of the peptide library using mass spectrometry allowed the identification of five  
25           hundred low molecular weight peptides

          In conclusion, we have the confirmation that the *Lb. helveticus* NCC 619 strain is able to generate peptides displaying bioactivity, as shown in the table above. This strain generated also more than five thousand low  
30           molecular weight peptides, all characterised by mass spectrometry. This peptide library, including peptides

from two to twenty-eight amino acids, displayed also a new bioactive potential, as will be shown later.

5 The peptide library generated in this work is not as wide as a random synthetic peptide library or even as a phage display library. The identified peptides however cover the complete protein sequence of the caseins. Proteolytic peptide libraries obtained with enzymes that show a broad specificity have the advantage to generate peptides of different length with overlapping amino acid sequences, thus increasing the chances of positive hits.

15

### Biological activity of caseinate hydrolysates

#### Cellular proliferation tests

20

The effect of caseinate hydrolysate on human colon cancer cell line HT-29 was investigated. This experimental set-up provides an experimental model in which it is possible to study, directly on the cells, the effects of fermented milk or fermented milk fractions.

25

For the first screening, HT-29 cells were incubated 24 hours with caseinate hydrolysates fermented for one, two and five hours with *Lb. helveticus* CNCM I-2864 (Table 2). All assays were performed in triplicate. Cell number was determined before and after incubation with caseinate hydrolysate, allowing

30

the distinction between inhibition of cell proliferation and induction of cell death.

The observed cell growth of HT-29 in cellular culture medium without serum was normalised. As positive control, cells were incubated in presence of foetal calf serum, this serum containing various growth factors. Finally, as negative control, cells were incubated 24 hours in physiological saline, without any cellular culture medium. After 24 hours incubation with the samples, the cells were dyed using neutral red.

Indeed, the supravital stain neutral red is weakly cationic and is thus actively concentrated by viable cells in intracytoplasmic vacuoles and granules by binding to anionic sites. It has been described as a convenient and reproducible assay to determine cell proliferation in 96-well plates.

	+ serum	- serum	0.9% NaCl	Casein ate	Tris malea te	CNCM I- 2864 0h	CNCM I- 2864 1h	CNCM I- 2864 2h	CNCM I- 2864 5h
% prolif	112 +/-17	100 +/- 9	-26 +/- 8	93 +/- 12	72 +/- 13	83 +/- 5	23 +/- 5	26 +/- 3	104 +/- 10

Table 2 : Effect of caseinate hydrolysates on growth of HT-29 cells. Results are expressed as percentage of OD (OD measured at 540 nm) with respect to the control (-serum).

As complementary controls, it was checked that neither sodium caseinate, the initial substrate, nor tris-maleate, the buffer used during caseinate hydrolysis had any negative effect on HT-29 cellular proliferation.

As we see from Table 2, sodium caseinate as well as tris-maleate had no activity towards cellular proliferation.

However, caseinate hydrolysates fermented for one and two hours showed high antiproliferative activity. This activity disappeared after 5 hours hydrolysis.

This particular feature indicates that some antiproliferative factors were generated during caseinate hydrolysis. They were then at their turn digested, and lost their bioactivity, explaining the disappearance of the antiproliferative properties of the caseinate hydrolysate at five hours fermentation. Thus antiproliferative factors present in the hydrolysates are probably of proteinic origin.

This hypothesis was examined (Table 3). A fraction showing antiproliferative activity was tested in parallel with the same fraction having been digested successively by alcalase and proteinase A, two commercially available enzymes.



	+ serum	- serum	0.9% NaCl	Casei nate	CNCM I-2864 1h	CNCM I-2864 1h, ΔT	(E,ΔT) + CNCM I-2864 1h	(CNCM I-2864 1h+E) ΔT
% prolif	121	100	5	93	28	13	31	100
	+/- 4	+/-8	+/-	+/-	+/-	+/-	+/- 6	+/-
			5	7	12	12		13

Table 3 : Effect of caseinate hydrolysates on growth of HT-29 cells. Results are expressed as percentage of OD (OD measured at 540 nm) with respect to the control (-serum).

CNCM I-2864, 1h : caseinate hydrolysate fermented for one hour with the *Lb.helveticus* CNCM I-2864 for one hour; CNCM I-2864 1h, ΔT: heat-treated caseinate hydrolysate; (E,ΔT) CNCM I-2864 1h: non-treated caseinate hydrolysate with addition of heat-inactivated enzyme; (CNCM I-2864 1h + E) ΔT: caseinate hydrolysate further hydrolysed with enzymes and finally heat-treated for enzyme inactivation.

The data presented in Table 2 show the effect on the proliferation of the colon cancer cell line HT-29 of an active fraction which has been further digested by commercially available enzymes. The enzymes were inhibited by heating.

In this specific experiment, the caseinate fraction fermented for one hour with *Lb. helveticus* CNCM I-2864. showed a reproducible inhibiting effect with 72% (previously 77%) inhibition of proliferation (Table 2 and Table 3).

The same fraction, that had undergone further enzymatic treatment with alcalase and proteinase A, lost its antiproliferative character.

In order to establish the validity of this result, we checked that the final heating step was not responsible for the loss of bioactivity.

5 If we make the assumption that the responsible factor is of proteinic origin, heating the sample could induce a change in the conformation of active proteins, leading to the non-recognition of the mentioned protein by a putative receptor involved in cellular proliferation mechanism. Thus, the active  
10 fraction was submitted to heating, without enzymatic treatment. The effect on cellular proliferation of this heated fraction was in all points similar to the ones of the non-heated hydrolysate. To reject any interference of the heat-inactivated enzymes in the  
15 test, the active fraction was mixed with heat-inactivated enzymes and the activity of the sample remained unaffected.

At this stage, we were not able to differentiate between an active proteinic factor generated by the  
20 lactic acid bacteria strain during caseinate hydrolysis or a casein-derived peptide. This differentiation will be made when mass spectrometric analysis of the samples will be performed.

25 Casein-derived hydrolysates are not cytotoxic

To be sure that the antiproliferative effect observed on the human colon cancer cell line was not the observation of the induction of necrosis,  
30 cytotoxicity tests were performed. Most current assays for measuring cytotoxicity are based on alterations of plasma membrane permeability and the consequent

release of cytoplasmic enzymes or the uptake of dyes, normally excluded by viable cells. We here chose to measure the lactate dehydrogenase (LDH) activity released from damaged cells (Table 4).

5

	Lysate	+ serum	- serum	Casei nate	Tris malea te	CNCM I- 2864 0h	CNCM I- 2864 1h	CNCM I- 2864 2h	CNCM I- 2864 5h
* prolif	100 +/-8	4 +/-2	0 +/-6	9 +/-3	-1 +/-4	-6 +/-6	-4 +/-7	-6 +/-3	-7 +/-3

Table 4 : Determination of the cytotoxic potential of caseinate hydrolysates on HT-29 cells. Results are expressed as percentage of OD (OD measured at 490 nm) with respect to the control (lysate).

No LDH activity was detected in any culture media of cells incubated 24 hours with caseinate hydrolysates. Based on this test, we may affirm that sodium caseinate hydrolysates did neither alter cell permeability nor induced necrosis.

Little LDH activity was however observed when cells were incubated in physiological saline only, showing that slight membrane alterations occurred as the result of harsh culture conditions.

Thus, considering these last results, we knew that sodium caseinate hydrolysates inducing a decreased colon cancer cell line proliferation were not cytotoxic.

Inhibition of cell proliferation by GPC fractions

Considering the results of the first proliferation  
test, we have seen that hydrolysates fermented for one  
and two hours with *Lb. helveticus* CNCM I-2864 had  
antiproliferative character.

In Table 5 we present the cellular growth experienced  
when testing fractions of a caseinate hydrolysate  
fermented for two hours and separated on a molecular  
weight basis.

	+	-	0.9 %	F1	F2	F3	F4	F5	F6	F7	C2
	serum	serum	NaCl								rec.
% prolif	122	100	13	97	108	95	102	104	54	62	29
	+/- 9	+/- 13	+/- 9	+/-	+/-	+/-	+/-	+/-	+/-	+/-	+/-
				-7	11	15	19	19	8	12	10

Table 5 : Effect of caseinate hydrolysate's gel  
chromatography fractions (two hours fermentation) on  
growth of HT-29 cells. Results are expressed as  
percentage of OD (OD measured at 540 nm) with respect  
to the control (-serum).

F1: 45'-40'000 Da peptides; F2: 40'-35'000 Da; F3: 35'-  
25'000 Da peptides; F4: 25'-15'000 Da peptides; F5:  
15'-5'000 Da peptides; F6: 5'-1'000 Da peptides; F7:  
peptides >1'000 Da. C2 Reconst: fraction reconstituted  
on the basis of F1-F7.

Fractions F1 to F5 from GPC represent peptides with  
molecular weights ranging from 45'-5'000 Da. These  
fractions did not contain any antiproliferative  
factors or these were present in insufficient quantity  
for detection.

On the contrary, F6 from GPC (corresponding to peptides: 5'-1'000 Da) and F7 from GPC (peptides <1'000 Da) showed important antiproliferative activities and were further investigated.

5

We notice moreover that isocratic fractionation using neutral ammonium acetate solution is a mild technique ensuring biological activity's preservation. Indeed, we did not loose biological activity through separation of the hydrolysate as a reconstituted fraction (C2 Reconst.) showed identical activity as before separation (Table 4).

10

Samples were analysed by mass spectrometry. We knew the exact peptidic content of each subfraction. Fractions showing antiproliferative potential, but inactive fractions too were characterised using mass spectrometry. Thus we searched for a peptidic sequence present in all slightly active subfractions derived from a sample having shown antiproliferative activity, but absent in a sample not having exhibited bioactivity.

15

20

This search was effected and the results are presented in Figure 1. Two potential candidates were identified, one sequence was derived from alpha-S1 and the other from beta casein.

25

Peptides from the candidate region retrieved in an inactive fraction are shown in black whereas peptides characterised in subfractions twenty-four to twenty-seven and showing activity are shown in grey.

30

Decision was taken to synthesize chemically the candidate active regions.

Alanine	Ala	A
Arginine	Arg	R
Asparagine	Asn	N
Aspartic acid	Asp	D
Cysteine	Cys	C
Glutamine	Gln	Q
Glutamic acid	Glu	E
Glycine	Gly	G
Histidine	His	H
Isoleucine	Ile	I
Leucine	Leu	L
Lysine	Lys	K
Methionine	Met	M
Phenylalanine	Phe	F
Proline	Pro	P
Serine	Ser	S
Threonine	Thr	T
Tryptophan	Trp	W
Tyrosine	Tyr	Y
Valine	Val	V

### Peptide synthesis

Peptides sequences VENLHLPLPLL, ENLHLPLPLL,  
 5 NLHLPLPLL and LLENLLRFFVAPFPEVFG, NENLLRFFVAPFPEVFG,  
 ENLLRFFVAPFPEVFG, FVAPFPEVFG were chemically  
 synthesised by Dr. A. Razaname at the EPFL, Lausanne  
 using the Fmoc-solid phase peptide synthesis strategy.

10 It was for chemical practical purposes that the  
 alpha-S1 casein sequence was elongated at the C-  
 terminus from phenylalanine to glycine.

### Inhibition of proliferation by synthetic peptides

15 Synthetic peptides that were tested on HT-29 cell  
 line confirmed their antiproliferative potential.  
 The tested peptide LLENLLRFFVAPFPEVFG ( $\alpha_{S1}$  31-48)  
 strongly inhibited proliferation (Table 6). The same  
 20 experiment was performed with a shorter version of the

former mentioned peptide: ENLLRFFVAPFPEVFG ( $\alpha_{S1}$  33-48). Best antiproliferative results were obtained at two to four micromolar concentrations, giving an antiproliferative pattern similar to the one observed for LNENLLRFFVAPFPEVFG (data not shown). On the basis of this data and for this particular sequence, N-terminus elongation was shown to preserve biological activity.

Peptide concentration [ $\mu$ M]	0	133	66	33	17	8	4	2
% prolif	100	135	119	131	114	160	44	56

Table 6 : Effect on growth of HT-29 cells of the alpha-S1 derived synthetic peptide: LNENLLRFFVAPFPEVFG ( $\alpha_{S1}$  31-48). Results are expressed as percentage of counts with respect to the control.

#### In vitro inhibition of MMPs

We chose to focus attention on MMP-2, -7 and -9. First, MMP-9 is involved in breast, colorectal, lung, prostate, pancreatic and ovarian tumors. Its expression is closely associated with the conversion from radial growth phase to vertical growth phase and subsequent metastasis. Secondly, MMP-2 is involved in breast, colorectal, lung, prostate, pancreatic and ovarian tumors. Its increasing expression indicates progressing tumor grade. Finally, MMP-7 is involved in

breast, colorectal, lung and prostate tumors. MMP-7 has been implicated in the early steps of tumor development.

5 Both families of synthetic peptides were tested for their potential as MMP inhibitors: the four peptides derived from casein alpha-S1 and the three derived from beta caseins.

As positive control we tested o-phenantroline, a broad  
10 metalloproteinase inhibitor, which showed complete MMP inhibition at 10 mM concentration (data not shown)

Inhibition data concerning MMP-2, MMP-7 and MMP-9 inhibition (Table 7) showed increasing inhibiting activities with increasing N-terminal length of  
15 peptides derived from beta casein.

Concerning MMP-2 and MMP-7, we observe an increasing inhibitory potential with N-terminal elongation of the ENLLRFFVAPFPEVFG sequence. However, this tendency is not confirmed in the case of MMP-9.

20 Moreover, FVAPFPEVFG showed an equal inhibitory potential for all three MMPs tested.

In general, we might observe relatively large IC<sub>50</sub> values differences between MMP-7 and MMP-9 or MMP-2.

25 These differences might be explained by the structural variation between these enzymes. In fact, MMP-7 is lacking the hemopexin-like domain. This domain has been shown to play a functional role in substrate binding and/or in interactions with the tissue inhibitors of metalloproteinases (TIMPs), a family of  
30 specific MMP protein inhibitors.



		IC <sub>50</sub> values [ $\mu$ M]		
		MMP-2	MMP-7	MMP-9
Derived from beta casein	NLHLPLPLL	450	1200	600
	ENLHLPLPLL	200	275	300
	VENLHLPLPLL	150	250	300
Derived from alpha-S1 casein	FVAPFPEVFG	500	300	400
	ENLLRFFVAPFPEVFG	425	1000	150
	NENLLRFFVAPFPEVFG	275	850	50
	LNENLLRFFVAPFPEVFG	250	300	150

Table 7 : IC<sub>50</sub> [ $\mu$ M] for the inhibition of MMPs using a fluorescein conjugated gelatin

5

#### In vitro inhibition of ACE

10

It is important to notice that ACE belongs to the zincin family of proteinases containing the **HEXXH** short binding consensus sequence, the family including matrix metalloproteinases too.

15

Inhibitors of matrix metalloproteinases might thus interfere with other zinc-metalloproteinases. We decided to test MMP-inhibitory peptides for their ACE-inhibitory potential.

20

	IC <sub>50</sub> values [ $\mu$ M] ACE
<i>Derived from beta casein</i>	NLHLPLPLL 15
	ENLHLPLPLL 250
	VENLHLPLPLL 175
<i>Derived from alpha-S1 casein</i>	FVAPFPEVFG 650
	ENLLRFEVAPFPEVFG 250
	NENLLRFFVAPFPEVFG 55
	LNENLLRFFVAPFPEVFG 280

Table 8 : IC<sub>50</sub> [ $\mu$ M] for the inhibition of ACE using the synthetic tripeptide substrate N-[3-2(furyl)acryloyl]L-phenylalanylglycylglycine.

From the data of Table 7 and that of Table 8 we notice a similar behaviour of alpha-S1 derived peptides concerning the inhibition of both ACE and MMP-9.

An identical behaviour for the inhibition of MMP-9 and ACE was displayed by peptides derived from the beta casein sequence.

## CLAIMS

1. Metallo-proteinases inhibitory agent, in particular a  
5 matrix-metalloproteinases inhibitory agent, comprising  
casein-derived peptides obtained by hydrolysis of casein by  
a food grade bacteria.
2. Process for the manufacture of a metalloproteinases  
10 inhibitory agent, in particular a matrix-metalloproteinases  
inhibitory agent, comprising the steps of :
  - preparing a solution of casein and food grade  
bacteria,
  - holding said solution under conditions effective to  
15 partially hydrolyse the casein to provide a  
metalloproteinases inhibitory agent, in particular a  
matrix-metalloproteinases inhibitory agent, containing  
casein-derived peptides,
  - stopping the hydrolysis and
  - 20 - optionnaly recovering the inhibitory agent from the  
solution.
3. Process according to claim 2, characterized in that the  
food grade bacteria is selected from the group consisting  
25 of *Lactobacilli* and *Bacilli*.
4. Process according to claim 2, characterized in that the  
food grade bacteria is selected from the group consisting  
of *Lactobacillus helveticus* ssp, and *Lactobacillus*  
30 *helveticus* CNCM I-2864.

5. Process according to claim 2, characterized in that isolated proteolytic enzymes of the preferred food grade bacteria are used instead of the bacteria or in combination with the bacteria.

5

6. Process for the manufacture of a fermented dairy product containing a metalloproteinases inhibitory agent, preferably matrix-metalloproteinases inhibitory agent, comprising the steps of :

10

- contacting lactic acid bacteria with milk,

- fermenting the obtained mixture to obtain a fermented dairy product, under conditions to partially hydrolyse the casein of the milk into casein-derived peptides to provide a fermented dairy product containing a metalloproteinases inhibitory agent, in particular a matrix-metalloproteinases inhibitory agent.

15

7. Inhibitors of metalloproteinases, in particular matrix-metalloproteinases, selected from the group consisting of the single-polypeptide-chain peptides set forth in SEQ ID N° 1 to 8, having the amino acid sequence:

20

25

E-N-L-L-R-F-F-V-A-P-F-P-E-V-F,

E-N-L-L-R-F-F-V-A-P-F-P-E-V-F-G-K-E-K-V,

N-E-N-L-L-R-F-F-V-A-P-F-P-E-V-F,

L-N-E-N-L-L-R-F-F-V-A-P-F-P-E-V,

E-N-L-L-R-F-F-V-A-P-F-P-E,

N-E-N-L-L-R-F-F-V-A-P-F-P-E,

G-L-P-Q-E-V-L-N-E-N-L-L-R-F-F and

30

F-V-A-P-F-P-E-V-F-G-K-E-K-V-N-E-L-S-K-D-I-G-S

8. Inhibitors of metalloproteinases, in particular matrix-metalloproteinases, selected from the group consisting of the single-polypeptide-chain peptides set forth in SEQ ID N°9 to 16, having the amino acid sequence:

5 L-H-L-P-L-P-L-L  
 L-H-L-P-L-P-L-L-Q  
 N-L-H-L-P-L-P-L-L-Q  
 N-L-H-L-P-L-P-L-L  
 N-L-H-L-P-L-P-L-L-Q-S-W  
 10 D-V-E-N-L-H-L-P-L-P-L-L-Q-S-W  
 V-E-N-L-H-L-P-L-P-L  
 V-E-N-L-H-L-P-L-P and  
 L-P-L-L-Q-S-W-M-H-Q-P-H-Q-P-L-P-P-T-V-M-F-P-P-Q-S

15 9. Use of the inhibitory agent according to claim 1 for systematical, local or topical inhibition of metalloproteinases, in particular matrix-metalloproteinases.

20 10. Use of the inhibitors according to claims 7 and 8 for systematical, local or topical inhibition of metalloproteinases, in particular matrix-metalloproteinases.

25 11. Use of inhibitors according to claims 7 and 8 or inhibitory agent according to claim 1, in toothpaste, mouth-bath or food products, such as fermented and non fermented dairy products like yoghourts or fermented dairy beverages, chewing-gums, candies, petfoods and oral  
 30 supplements.

12. Use of the inhibitors according to claims 7 and 8 or inhibitory agent according to claim 1 for the manufacture of a drug for reducing feline osteoclastic resorptive lesions.

5

13. Pharmaceutical composition comprising an effective amount of inhibitors according to claims 7 and 8 or inhibitory agent according to claim 1 for reducing activities and/or functions of metalloproteinases, in  
10 particular matrix-metalloproteinases.

**B**[illegible]

### FIGURE 1

## SEQUENCE LISTING

<110> SOCIETE DES PRODUITS NESTLE S.A.

5

<120> Metallo protease inhibitors

10 <130> 7246 EP

15

<160> 16

20

<170> PatentIn version 3.1

25

<210> 1

<211> 15

<212> PRT

30

<213> Bos taurus

<400> 1



Glu Asn Leu Leu Arg Phe Phe Val Ala Pro Phe Pro Glu Val Phe  
1 5 10 15

5

&lt;210&gt; 2

&lt;211&gt; 20

10 &lt;212&gt; PRT

&lt;213&gt; Bos taurus

15

&lt;400&gt; 2

Glu Asn Leu Leu Arg Phe Phe Val Ala Pro Phe Pro Glu Val Phe  
Gly

20 1 5 10 15

Lys Glu Lys Val  
20

25

&lt;210&gt; 3

&lt;211&gt; 16

30

&lt;212&gt; PRT

<213> Bos taurus

5 <400> 3

Asn Glu Asn Leu Leu Arg Phe Phe Val Ala Pro Phe Pro Glu Val  
Phe

1 5 10 15  
10

<210> 4

<211> 16

15

<212> PRT

<213> Bos taurus

20

<400> 4

Leu Asn Glu Asn Leu Leu Arg Phe Phe Val Ala Pro Phe Pro Glu  
Val

1 5 10 15  
25

<210> 5

30

<211> 13

<212> PRT

<213> Bos taurus

5

<400> 5

Glu Asn Leu Leu Arg Phe Phe Val Ala Pro Phe Pro Glu

10 1 5 10

<210> 6

15 <211> 14

<212> PRT

<213> Bos taurus

20

<400> 6

25 Asn Glu Asn Leu Leu Arg Phe Phe Val Ala Pro Phe Pro Glu

1 5 10

<210> 7

30

<211> 15

<213> Bos taurus

<400> 7

<210> 8

15      <211>      23

<212> PRT

<400> 8

30    Leu Ser Lys Asp Ile Gly Ser  
                20

<210> 9

<211> 8

5

<212> PRT

<213> Bos taurus

10

<400> 9

Leu His Leu Pro Leu Pro Leu Leu

15

1

5

<210> 10

20

<211> 9

<212> PRT

<213> Bos taurus

25

<400> 10

30

Leu His Leu Pro Leu Pro Leu Leu Gln

1

5

<210> 11

<211> 10

5

<212> PRT

<213> Bos taurus

10

<400> 11

Asn Leu His Leu Pro Leu Pro Leu Leu Gln

15

1

5

10

<210> 12

20

<211> 9

<212> PRT

<213> Bos taurus

25

<400> 12

30

Asn Leu His Leu Pro Leu Pro Leu Leu

1

5

<210> 13

<211> 12

5

<212> PRT

<213> Bos taurus

10

<400> 13

Asn Leu His Leu Pro Leu Pro Leu Leu Gln Ser Trp

15

1

5

10

<210> 14

20

<211> 15

<212> PRT

<213> Bos taurus

25

<400> 14

30

Asp Val Glu Asn Leu His Leu Pro Leu Pro Leu Leu Gln Ser Trp

1

5

10

15

<210> 15

<211> 10

5

<212> PRT

<213> Bos taurus

10

<400> 15

Val Glu Asn Leu His Leu Pro Leu Pro Leu

15

1

5

10

<210> 16

20

<211> 9

<212> PRT

<213> Bos taurus

25

<400> 16

30

Val Glu Asn Leu His Leu Pro Leu Pro

1

5